Home / Business and Economy / Weight-Loss Pill Race: Lilly Chasing Novo Nordisk Lead
Weight-Loss Pill Race: Lilly Chasing Novo Nordisk Lead
15 Jul
Summary
- Novo Nordisk's Wegovy pill shows higher average weight loss.
- Lilly's Foundayo pill is catching up with broader coverage.
- Foundayo sales forecasts reduced, Wegovy's significantly increased.
The pharmaceutical industry is witnessing intense competition in the weight-loss drug market, with Novo Nordisk's Wegovy pill currently outpacing Eli Lilly's Foundayo. As of July 2026, Wegovy commands a larger prescription volume, reportedly due to superior efficacy, with patients losing an average of 16.6% body weight compared to 12.4% for Foundayo.
Eli Lilly faced initial challenges, including delays in securing health plan reimbursement for Foundayo. However, by early June 2026, the drug was covered by major pharmacy-benefit managers, a crucial step expected to boost sales. Lilly is actively promoting Foundayo, having aired its first TV advertisement in June 2026 during the NBA playoffs, aiming to increase physician awareness and patient adoption.
While Novo Nordisk holds an early lead, the race is far from over. Many analysts believe Lilly's Foundayo has the potential to surpass Wegovy globally, owing to its easier large-scale manufacturing. JPMorgan anticipates sales will accelerate next year as Lilly expands Foundayo's availability to over 40 international markets. The overall anti-obesity market, estimated at nearly $80 billion, is a significant battleground for major pharmaceutical companies.
